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Chromosomal localization of the protein tyrosine phosphatase Gl gene and 
characterization of the aberrant ranscripts in human colon cancer cells 
Abstract 
We have recently described the isolation of the human PTPGI gene which encodes a member of mtracellular protein tyrosme phosphntases that 
may be candidates for tumor suppressor genes. In order to investigate the abnormality of the PTPGl transcript m various human cancer cell lines, 
we have analyzed the consensus catalytic region of PTPG1 cDNA, using the reverse transcriptionpolymerase chain reaction. In a colorectal carcinoma 
cell line. DLD-I, we found three aberrant transcripts. Sequencing analysis revealed that one had a missense point mutation and tbe remainders 
contained 77 bp and 173 bp deletions. respectively. These alterations might directly affect their phosphatase activities. Our findings provtde the first 
evidence for the aberrant ranscripts of the protetn tyrosine phosphatase m human cancer cells, and suggest hat the aberration of PTPGJl gene might 
be invotved in the tumororigenesis. Moreover. the human PTPGI gene is localized on chromosome ?qt 1.23, a region with frequent abnormalities 
zmpticated in some human cancers. 
Key &so&: Protein tyrosine phosphatase; Point mutation; Alternative splicing; Human chromosome 7 
1. Introduction 
Protein tyrosine phosphatases (PTP) and protein tyro- 
sine kinases (PTK) are involved in the regulation of tyro- 
sine phosphor~latio~-mediated signaling. Such signaling 
is critical for the regulation of cell proliferation, differen- 
tiation and neoplastic transfo~ation f1,2]. Tyrosine 
phosphorylated proteins can be specifically dephos- 
phorylated through the action of PTP’s [3-51, which are 
therefore likely to have as important a role as PTKs in 
the control of cellular growth and differentiation. Fur- 
thermore, given that hyperphosphorylation of protein 
tyrosine residues can cause cell transformatian, it is plau- 
sible that lack of dephosphorylation resulting from loss 
of a PTP function may also wreak an oncogenic effect. 
Indeed, various lines of evidence have linked PTPs to cell 
cycle regulation, cell proliferation. and malignant trans- 
formation [6-9]. These studies suggest that PTPs may be 
candidates fr tumor suppressor genes. 
We have previously isolated a human PTPGl cDNA 
encoding a 88 kDa protein tyrosine phosphatase from an 
adult colon tissue cDNA library IlO] and the other group 
have recently reported isolation of the virtually identical 
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gene from HeLa cell [ 111, PTPGl belongs to a subfamily 
of intracellular PTPs and is characterized by following 
features: a long non-enzymatic domain located at the 
C-terminus which includes PEST sequences encoding 
proteins of short half-life in eukaryotes [lZ]; and some 
potential phospho~lation sites for cdc2 kinase, casein 
kinase II and double-stranded DNA-dependent kinase. 
The existence of the latter suggests that P’TPGI is regu- 
lated through phospho~lat~on in the cell cycle or by 
some mitogenic stimulation [lo]. 
Cytogenetic studies of cancer cells have revealed an 
association between the accumulation of several genetic 
changes and the tumorigenic process [ 131. In view of the 
potential importance of PTPs in tumorigenesis, we have 
used RT-PCR to investigate whether the PTPGl gene 
could be altered in a tumor-associated manner. Here we 
report the presence of aberrant transcripts of PTPGI in 
colon carcinoma cells and the characterization of its 
structure. In addition, we report that the chromosomal 
locus of the PTPGl gene was mapped to a region of 
human chromosome 7q I 1.23. 
2. Materials and methods 
All of the cell lrnes used for these studies were obtained from the 
Japanese Cancer Research Resources Bank (Tokyo). The cells were 
mamtamed in RPhII1640 containing 10% FCS, with the exception of 
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those noted. Colo320DM, WiDr, BM314, HeLa, CV-1 and NIH3T3 
were maintained in Dulbecco’s modified MEM containing 10% FCS, 
and SW948 and SW1474 were in L15 containing 10% FCS. The distinct 
clones of DLD-1 were isolated by selecting &lonies growing in soft 
agar. as described previously [14]. 
2.2. Isolation of RNA and Northern blot analysis 
Total RNA was prepared from human cell lines by the procedure of 
Chomczynsky and Sacci [15]. About 10,ug of total RNAs were electro- 
phoresed in 1 .O% agarose formaldehyde gels and blotted onto nitrocel- 
lulose filters. The filters were hybridized overnight at 42°C with a 
32P-labelled full-len~h cDNA probe, as previously described [lo]. 
2.3. Polymerase chaipl reaction, ~bc~on~ng and sequen&~ng of PTP 
domain 
Total RNA from various human cell lines were converted to double- 
stranded cDNA with random hexamers and Moloney murine leukemia 
virus reverse transcriptase. These cDNAs were used as templates for 
in vitro amplification with Taq DNA polymerase and PTPGl specific 
oligonucleotides (5’-AATGGGGAGGACAACTTCG-3’ as a sense 
primer, S-TTGGGCAATAGCTCTATGAAC-3’ as an anti-sense 
primer) and p-actin specific oligonucleotides (5’-CTGTCTGGCGGC- 
ACCACCAT-3’ as a sense primer, 5’-GCAACTAGTCATAGTCCG- 
C-3’ as an anti-sense primer). The PCR was carried out under the 
following conditions: denatured at 94°C for 1 min, annealed and ex- 
tended at 60°C for 1 min: 30 cvcles for PTPGl: 20 cvcles for 8-actin. 
Fragments of approximately 800 bp, which cover th; whole datalytic 
domain of PTPGl, were isolated from a low-melting- point agarose gel, 
subcloned into pBlue~ript SK- plasmid (Stratagene) and sequenced. 
The nucleotide sequence was determined in both directions by the chain 
termination method with a Sequenase kit using 7-deaza-2’-deoxy-CTP 
(USB). In DLD-1, the PCR reactions were independently performed 
twice and sequenced at least three clones from each reaction for any 
DNA fragment o ensure against reverse trandscription or Taq polym- 
erase artifacts. 
2 4. Southern blot analysis 
Genomic DNAs from various cell lines and tissues were extracted by 
protemase K digestion, phenol-chloroform extraction and ethanol pre- 
cipitation. Ten gg of genomic DNA was digested with the restriction 
endonucleases Ben, EsaHI, Hi&, PstI and BarnHI. The blot was hy- 
bridized to the 32P-labelled 0.6 kb cDNA fragment from 5’ side clone, 
;lGl-C2 [lo], or 3.0 kb of full-length PTPGl cDNA and subjected to 
autoradio~raphy for two days. 
2.5. Expression of the PTPGI protein and the antrbody preparation 
GST-PTPGI constructs were generated in order to express the 
PTPGl in E. coli. The N-terminal 1.5 kbp EcoRI fragment (correspond- 
mg to amino acids l--493), or the C-terminal 1.4 kbp EcoRI fragment 
(corresponding to amino acids 515-780) was fused in frame to the 
glutathione+transferase gene in the pGEX vector. The fusion proteins 
were purified by affinity chromatography on a glut&none column [16]. 
Each of the purified fusion proteins (400 pg per rabbit) was injected 
subcutaneously with complete Freund adjuvant into two female New 
Zealand rabbits. Booster immunizations were given at 2-week intervals 
with 200 pg of the same preparation in incomplete Freund adjuvant. 
After the third boost, the IgG fraction was prepared from antisera using 
Wattman DES2 gel ion~x~hange chromatography. 
2.6. ~rnrn~~ob~ottin~ and imrn~no~reei~ltat~on 
The cells were washed with ice-cold phosphate-buffered saline and 
immediately lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM 
NaCl. 1% NP40, 0.1% sodium deoxycholate, 4 mM EDTA, 10 mM 
NaF, 10 mM Na,P>O,, 2 mM Na,VO,. 1 mM PMSF, 1 &ml leupeptin, 
lO,~g/ml soybean trypsine inhibitor, lO,~g/ml tosyl phenylalanine chlo- 
romethyl ketone, 1 ,ug/ml aprotinin) at 4°C for 30 min. After removal 
of cell debris by centrifugation (12,000 x g, 30 min), lysates were im- 
mediately boiled for 5 min in sample buffer. For immunoblottmg. 
protein (150 pg) from each lysate -was fractionated on 10% polii 
acrylamide gels, transferred to a PVDF filter (Immobilon-P, Millipore), 
and then probed with the appropriate antibody. After three washes with 
TBST (20 mM Tris, pH 7.5,150mM NaCl, 1% Tween 20). PTPGl was 
visualized by incubation of the immunoblot with alkaline phosphatase- 
conjugated anti-rabbit antibody (Sigma) followed by 5-bromo-4- 
chloro-3-indoyl-phosphate and Nitroblue tetrazolium treatment. 
For immunoprectpitation, K562 ceils were labeled for 4 h in methion- 
ine-free RPM1 1640 containing 1 mCi of [3SS]methionine (100&i . ml-‘, 
1200 Ci . mmol-‘; NEN). The labeled cells were lysed at 4°C in 1 ml 
of lysis buffer. The lysates were centrifuged at 12,000 x g for 30 min at 
4”C, and aliquots of the supematants were used for immunoprecipita- 
tion 8 fig of the antibody was added to the labeled cell lysates and 
incubated for 1 h at 4°C. The immune complexes adsorbed to protein 
G-Sepharose were washed extensively with lysis buffer, and then ana- 
lyzed by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
followed by fluorography. 
2.7 ~hromosomal mapping 
Normal female metaphase chromosomes were obtained by thymidine 
synchroni~tion bromo-deoxyu~dine r lease. The probe, pG1, contain- 
ing a 3.0 kb fragment of the full-length human PTPGi cDNA, was 
labeled by nick translation. Fluorescence in situ hybridization was 
performed as described by Pinkel et al. 1171. The fluorescent signals of 
hybrid probes were amplified with avidin-fluorescein isothiocyanate 
(Boehringer, Mannheim, Germany) and biotynylated anti-avidineD 
(Vector, Burlingame, CA) according to the same protocols [17]. 
3. Results 
3.1. Expression of aberrant PTPGI transcripts in cancer 
cells 
We perfomed reverse transcription-polymerase chain 
reaction (RT-PCR) to investigate whether abnormal 
transcripts of PTPGI gene can be found in human cancer 
cells. The sequence of the 3.0 kb cDNA encoded by the 
human PTPGl gene had already been determined [lo]. 
A pair of oligonucleotide primers that amplified the re- 
gion encompassing the phosphatase domain coding se- 
quence, corresponding to nucleotides 86-895, were syn- 
thesized. Fig. i shows the primers and the RT-PCR 
products generated from various human cancer cell lines. 
Using the primers, we detected a single band in all 
human cancer cell lines except for a colon cancer line, 
DLD-1. Interestingly, we found three products from 
DLD-1 mRNA, one of the expected size (approximately 
8 10 bp, named DCl), a second, less abundant fragment, 
of about 730 bp (named DC2) and a third, equally abun- 
dant fragment, of about 630 bp (named DC3) (Fig. la). 
Thus, DLD-1 cells appear to contain three forms of the 
PTPGl transcript, suggesting that the PTPGl gene of 
DLD-1 may encode some abnormal phosphatase do- 
mains. 
Since a previous report demonstrated that DLDl cells 
were heterogenous and could be divided into two clones, 
A and D [14], we tested whether these aberrations oc- 
curred in both clones after subcloning of DLD-1 cells. 
The aberrant transcripts shown in Fig. 1 were subse- 
quently detected in both cloned lines (data not shown); 
however, no significant abnormalities could be found by 
Northern blot analysis using total RNA (data not 
shown). 
3.2. Nucleotide sequences of the aberrant transcripts in 
DLL)-1 cells 
To characterize the primary structure of the aberrant 
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Fig, 1. (a) Expressron of PTPGI mRNA in various cell hnes and aberrant PTPGl transcripts in the phosphatase domain from DLD- 1. One pg of 
total RNA extracted from cells was used for RT-PCR. p-Actin mRNA was used as an internal control. The sizes of PCR products are indicated 
on the right. Analyzed cell lines are as follows: (1) negative control; (2) Co1038; (3) Colo201; (4) Colo320DM; (5) Colo320HSR; (6) SW948; (7) 
SW1474: (8) DLD-1; (9) WiDr; (10) CHCYl; (11) BM314; (12) KATOIII; (13) MKNl; (14) MKN28; (15) MKN74; (16) NUGC3; (17) HUH7; (18) 
CHC4; (19) CHC32; (20) HLE: (21) Chang; (22) Molt3; (23) Molt4; (24) HL60; (25) Daudi; (26) K562. (b) Positions of the primers used are shown 
above a schematic dtagram of the predicted protein structure of normal PTPGl. Numbers refer to nucleotide positions of domain bounderies. 
transcripts in DLD-1 cells, each of the PCR fragments to-arginine). DC2 and DC3 transcripts did not contain 
from DLD-1 was subcloned and sequenced. Sequencing the point-mutations, but had deletions of 77 bp and 173 
analysis revealed that the DC1 transcript contained a bp, respectively, corresponding to nucleotides 228-304 
single-nucleotide change at positions 201 (A-to-G) (Fig. and 228400 of the authentic PTPGl gene transcript 
2a). This point-mutation resulted in a single amino acid (Fig. 2b). Each of the deletions resulted in a frame shift, 
substitution, or a missense mutation at codon 61 (lysine- and a termination codon (TAA or TGA) was found at 
a b 
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Fig. 2. Abnormalities of PTPGl transcripts encompassing the phosphatase domain in DLDl cells. (a) Sequencing analysis of the DC1 fragment from 
DLDl and wild-type (WT) PTPGl cDNA. The asterisk marks the A-to-G substitution in the DC1 sequence. Sequence from DC1 RT-PCR product 
show a single-nucleotide change at positron 201. (b) Comparison of the nucleotrde (nt) and predicted amino acid (aa) sequences containing a portion 
of the phosphatase domain in PTPGl of wild-type, DC2 and DC3. Sequences from DC2 and DC3 show 77 bp and 173 bp deletions, respectively. 
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Fig. 3. Southern blot analysis of the PTPGl gene. Ten pg of genomic DNA from normal colon tissues (lanes 1,4,7, 10 and 13). COL0320DM (lanes 
2, 5, 8, 11 and 14) and DLD-1 (lane 3, 6, 9, 12 and 15) was hybridized with a 0.6 kb fragment from 1Gl-C2. DNA was digested with Bcfi (lanes 
l-3), BsaHI (lanes 46). Hid (lanes 7-9), PstI (lanes 10-12) and BamHI (lanes 13-15). Numbers indicate the size of DNA markers in kb. 
a position 391 (for DC2) or 427 (for DC3) of the authen- 
tic cDNA. Therefore, the smaller PTPGl transcripts, 
DC2 and DC3, may encode the truncated PTPGl pro- 
teins with additional 29 and 9 amino acids following 
amino acid no. 69, respectively (Fig. 2b). 
3.3. Southern blot analysis of the PTPGI gene 
Southern blot analysis of genomic DNA was per- 
formed to confirm whether aberrant PTPGl transcripts 
in DLD-1 cells are ever produced by rearrangement of 
PTPGl gene. The 0.6 kb fragment of PTPGl cDNA (see 
section 2), which covered the deleted regions, was used 
as a probe. The sizes of the resulting bands were the same 
among the DNAs from DLD-1, COL0320DM and a 
normal colon tissue when digested with some restriction 
enzymes whose sites were located in the deleted regions 
or beside them (Fig. 3). No rearrangement or amplifica- 
tion of PTPGl gene was detected when the full-length of 
a b c d 
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Fig. 4. Characterization of polyclonal antibodies to PTPGl and the immunoreactive protein in various cell lines. Total cellular protein lysates from 
various cell lines were prepared and examined for PTPGl protein expression by Western blotting and immunoprecipitation. The positions of protein 
markers are indicated in kilodaltons. (a) Cell lysates from HeLa (lanes 1 and 5), K562 (lanes 2 and 6), CV-I (lane 3), NIH3T3 (lane 4) were separated 
by SDS-polyacrylamide gel electrophoresis, blotted to PVDF filter, and detected using the anti-PTPGl N-terminal antibody (lanes 14) or anti-PTPGl 
C-terminal antibody (lanes 5 and 6). (b) Immunoprecipitation of PTPGl from “S-labeled cell extracts of KS62 (lanes l-3). Cells were labeled for 
4 h with [35S]methionine and then lysed in lysis buffer. The PTPGI proteins were immunoprecipitated with antibodies against GST-PTPGl-N and 
analyzed by SDS-PAGE followed by fluorography. Antibodies were blocked by preincubation with the fusion polypeptides used for immunization 
(lane 2) or GST alone (lane 3). (c) Immunoblotting ofPTPGl protein immunoprecipitated from lysates of K562. Immunoprecipitated PTPGl proteins 
were separated on SDS-PAGE, and then detected by imunoblotting using anti-PTPGl N-terminal antibody. (d) Western blot analysis of truncated 
PTPGI protein in DLDl cells. The extract of KS62 cells was electrophoresed as a control (lane 1). The truncated PTPGl proteins were detected 
at 32 kDa in both clones of DLDl (lane 2; clone A, lane 3; clone D), using anti-PTPGI N-terminal antibody. Whereas the proteins of 32 kDa were 
not detected in DLD-1 using anti-PTPGl C-terminal antibody (lane 4). 
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PTPGl cDNA was used as a probe (data not shown). 
These results suggest that s ructural rearrangement of 
the PTPGl gene does not occur in DLD-1 cells, although 
further genomic analysis of PTPGl will be required to 
confirm it. 
3.4. Abnormal expression of the PTPGI gene products in 
DLD-1 cells 
We raised polyclonal antibodies against two bacterial 
fusion proteins, the N-terminal half (amino acids 1493) 
and the C-terminal half (amino acids 515-780) of the 
PTPGl protein, to examine the translation products of 
PTPgl directly. First, Western blot analysis was per- 
formed to test whether these two antibodies specifically 
detected the PTPGl protein. Both antibodies detected a 
single molecular species of 88 kDa from extracts of var- 
ious cell lines (Fig. 4a), which was equivalent with that 
predicted from PTPGl cDNA nucleotide sequence [lo]. 
To further confirm the specificity of the antibodies, we 
examined whether they could immunoprecipitate the 
PTPGl proteins. Antibodies against the N-terminal re- 
gion precipitated the 88 kDa protein from extracts of 
K562 cells labeled with ~35S]methionine (Fig. 4b). Fur- 
thermore, recognition of the 88 kDa band was strongly 
blocked by preincubation of the antibodies with an ex- 
cess of the fusion protein used for immunization, gluta- 
thione-S-transferase-PTPGI-N-terminal (GST-PTPGl- 
N), but not by preincubation with the glutathione-S- 
transferase (GST) protein alone (Fig. 4b). Several other 
bands seen in Fig. 4b were non-specific. since these were 
not found when immunoprecipitated proteins were ana- 
lyzed by immunoblotting with the same antibody (Fig. 
4~). These results indicate that these antibodies are spe- 
cific to the PTPGI protein. 
Western blot analysis was carried out to characterize 
the protein product of the PTPGl gene in DLD-1 cells. 
K562 cells express a single molecular species of 88 kDa, 
Fig. 5. (A) Fluorescence in situ hybridization of the PTPGl gene. 
Double fluorescent spots were detected on R-banded chromosome 7 at 
the q11.23 region. (B) The same metaphase chromosomes after G- 
bandmg. 
whereas two immunoreactive bands of 88 kDa and 32 
kDa, respectively, were detected in lysates from DLD-1 
cells by using the antibodies against the N-terminal re- 
gion (Fig. 4d). While the antibody against he C-terminal 
region was used as the probe, the band of 88 kDa, but 
not the band of 32 kDa, was detected in DLD-1 cells 
(Fig. 4d). These data suggest that the C-terminal trun- 
cated PTPGl protein may be expressed in DLD-1. 
3.5. Chromosomal mapping of the human PTPGI gene 
Fluorescence in situ hybridization was performed 
using pG1 containing the 3.0 kb PTPGl cDNA [IO] to 
determine the chromosomal ocalization of the PTPGl 
gene. When 50 metaphase spreads were examined, 42 of 
them (84%) showed either single or double spots of fluo- 
rescent signals on the proximal portion of the long arm 
of human chromosome 7 (Fig. 5A).. No constant fluores- 
cence signal was seen with any other chromosomes. By 
comparison with the G-banding patterns (Fig. 5B), the 
human PTPGl gene was assigned to chromosome 
7qll.23. 
4. Discussion 
The human PTPGl gene is one of the intracellular 
protein tyrosine phosphatases, which are believed to play 
a crucial role in signal transduction [10,111. Various lines 
of evidece suggest that PTP may act as a tumor suppres- 
sor gene [18-211. We have previously shown that PTPGl 
mRNA was expressed in various cell lines using North- 
ern blot analysis [lo]. RT-PCR was employed here to 
further investigate the alterations of the PTPGl expres- 
sion in human cancer. We found the aberrant PTPGI 
transcripts in colon cancer cells to reveal its primary 
structure. It is of interest that three altered transcripts 
(here designated DCl, DC2 and DC3) were detected 
within the phosphatase consensus region of PTPGl 
cDNA from DLD-1 cells. 
The DC1 transcript whose size was equal to that from 
the authentic PTPGl cDNA contained a point-mutation 
which resulted in a single amino acid substitution at 
codon 61, lysine-to-arginine, a finding that may have 
implications for the gene product function. The order 
two smaller fragments, DC2 and DC3, had deletions for 
which the protein products were predicted to be out of 
frame and prematurely truncated in the phosphatase do- 
main. Interestingly, in both cases of DC2 and DC3, the 
deletions of these two transcripts started at the same 
nucleotide 228. In addition, no gross rearrangement or 
amplification of PTPGl gene could be found in DLD-1 
by Southern blot analysis using the cDNA probes. These 
results raise the possibility that the truncated transcripts 
are generated by abnormal splicing, rather than by dele- 
tion or recombination. Since point-mutations revealed in 
the DC1 were not detected in DC2 or DC3, the latter two 
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transcripts may originate via abnormal splicing in one 
allele and DC1 transcript in the other. Interestingly, re- 
cent studies have demonstrated that point-mutations 
around the splice junctions in the murine protein phos- 
phatase gene, HCP, leading to abnormal splicing in the 
phosphatase domain and the src homology 2 domain, 
which are associated with severe combined immunodefi- 
ciency and systemic autoimmunity in moth-eaten and 
visable moth-eaten mice [22,23]. Furthermore, mutations 
at analogous splice site positions in some tumor suppres- 
sor genes, including ~53, APC, MCC, etc., have been 
shown to alter RNA processing in vivo and in vitro 
[24-261. Actually, a sequence at the end of the deleted 
region in DC2 is A_,A_,G_,G_,, which matches the con- 
served 3’ splice site consensus sequence (C1 
T_3A_zG_,G+,) at three out of four positions [27], and 
therefore potentially acts as the appropriate sequence 
context for use of the AG dinucleotide as a 3’ acceptor 
site. It is plausible that DLD-1 could have other abnor- 
malities associated with the splicing signal sequences, 
such as mRNA species missing the 77 bp or the 173 bp 
segment. 
The truncated proteins translated from aberrant tran- 
scripts DC2 and DC3 would be expected to consist of 98 
or 78 amino acids. To confirm their expression at the 
protein level, Western blot analysis was performed. Two 
immunoreactive bands of 88 kDa and 32 kDa were de- 
tected in lysates from DLD-1 cells, using antibodies 
against the N-terminal region, whereas the 32 kDa band 
was not detected in lysates from control cells or using the 
antibodies against the C-terminal region. These results 
suggest that the C-terminal truncated PTPGl protein of 
32 kDa could be expressed in DLD- 1. Although we can- 
not exclude the possibility that the 32 kDa band is seen 
by cross-reaction of the antibodies because the sequence 
predicted 98 or 78 amino acid polypeptides with pre- 
dicted molecular sizes of approximately 10 kDa, there 
appears to be at least two possibile explanations for this 
discrepancy: (i) mobility shifts resulted from a post- 
translational modification such as phosphorylation, gly- 
cosylation. etc.; or (ii) additional abnormal polypeptides 
translated at the further upstream site of the PCR- ampli- 
fied region. Further studies on the protein alterations of 
PTPGI in DLD-1 must be required to confirm it. 
The human colon carcinoma cell line DLD-1 was es- 
tablished from a moderately to poorly differentiated 
adenocarcinoma of the sigmoid colon [14]. It was previ- 
ously indicated that both the DLD-1 cell line and the 
original tumor were heterogeneous and the former could 
be divided into two clones, A and D. Clone A is charac- 
terized by poorly differentiated histology, hyperploid 
karyotype and fuzzy star-shaped colony formation in 
soft agar, and clone D, by moderately differentiated his- 
tology, diploid karyotype and small spheroid colony for- 
mation in soft agar [14]. Since aberrant trandscripts and 
C-terminal truncated protein were detected in both 
clones, genetic alterations might occur in the original 
primary tumor as somatic mutations. The pathological 
meaning of the abnormal transcripts is still unclear, but 
if alterations in enzymatic activity among them exist, the 
regulation of certain specific substrates participating in 
molecule to molecule interaction might be disturbed. De- 
fective PTPGl expression in cancer cells would be ex- 
pected to result in altered levels of phosphorylated tyro- 
sine residues, which might be involved in tumorigenesis. 
Fluorescence in situ hybridization using PTPGl 
cDNA revealed that the human PTPGl gene is located 
at 7qll.23. This region is of particular interest because 
it is a common site of chromosomal rearrangements in 
malignant melanoma [28,29] and resides near the recur- 
rent breakpoints in some hematopoietic disorders includ- 
ing acute lymphoblastic leukemia, malignant lymphoma, 
etc. [30]. Moreover, this locus is known to be aphidicolin- 
induced fragile sites, which are frequently located at or 
near breakpoints of chromosomal rearrangements found 
in tumor cells [31]. Allelic deletions of 7q have been 
reported in some solid tumors including colorectal carci- 
nomas [32,33]. Interestingly, the gene for Zellweger syn- 
drome, an autosomal recessive disorder that affects gen- 
eration of the peroxisomal membrane, has been located 
in the same region [34,35]. Abnormalities of this locus 
may be associated with these disorders as a result of the 
alteration of the PTPGl gene. Recently, a human trans- 
membrane PTPC was assigned to chromosome 7q3 l-33 
[36], suggesting that there may be a family of PTPs on 
chromosome 7. 
A previous study revealed that abnormal sized 
mRNAs of a transmembrane PTPy were expressed in a 
human lung cancer cell line and a osteosarcoma cell line 
using Northern blot analysis [37]. However, RNase pro- 
tection assay and PCR-SSCP of the cytoplasmic region 
which contains phosphatase domains showed no nucleo- 
tide changes in these cancer cell lines [37]. Therefore, the 
colon carcinoma cells described here eppear to be first 
known case of a human tumor in which the protein 
tyrosine phosphatase is altered at the nucleotide se- 
quence and protein levels. Analysis of the altered PTPGl 
gene may prove helpful in studying the function of the 
normal gene product. However, the molecular genetic 
events that have occurred during the formation of tumor 
are now providing a new framework within which to 
consider the etiology of human cancer. Our results raise 
the possibility that the PTPGl gene is a target of the 
mutation in colorectal carcinoma. Further mutational 
analysis in clinical primary tumors as well as experiments 
to evaluate the biological effect of altered PTPGl genes 
on the colorectal tumor cells will be required. 
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